Related Experiment Videos
Hormonal therapy trials in prostatic cancer. An EORTC Genitourinary Group study
1Service du Chirurgie Urologique, Strasbourg, France.
American Journal of Clinical Oncology
|January 1, 1988
Summary
For metastatic prostate cancer, endocrine treatments show similar survival outcomes. Orchiectomy is the most cost-effective and safest option, with prognosis determined by patient risk groups, not complex labs.
Area of Science:
- Urology
- Oncology
- Clinical Trials
Background:
- The European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group has conducted trials for metastatic prostate cancer.
- Endocrine therapies are a cornerstone in managing advanced prostate cancer.
Purpose of the Study:
- To review completed and ongoing EORTC Genitourinary Group trials for metastatic prostate cancer.
- To evaluate the efficacy and identify prognostic factors for endocrine treatments.
Main Methods:
- Review of EORTC Genitourinary Group trial data.
- Statistical analysis of variables from trials 30,761 and 30,762.
- Comparison of outcomes (time to progression, survival) across different endocrine treatments.
Main Results:
- No significant differences in time to progression or survival were observed among effective endocrine treatments.
- Statistical analysis identified three distinct risk groups for patients.
- Prognosis can be established without specialized laboratory investigations.
Conclusions:
- Effective endocrine treatments for metastatic prostate cancer offer comparable survival benefits.
- Patient risk stratification is achievable through established variables, simplifying prognostic assessment.
- Orchiectomy emerges as the most economical and safest endocrine treatment option.